Skeletal sequelae of cancer and cancer treatment

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Unit 1461, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Journal of Cancer Survivorship (Impact Factor: 3.3). 06/2009; 3(2):75-88. DOI: 10.1007/s11764-009-0083-4
Source: PubMed


Survivors of cancer may experience lingering adverse skeletal effects such as osteoporosis and osteomalacia. Skeletal disorders are often associated with advancing age, but these effects can be exacerbated by exposure to cancer and its treatment. This review will explore the cancer and cancer treatment-related causes of skeletal disorders.
We performed a comprehensive search, using various Internet-based medical search engines such as PubMed, Medline Plus, Scopus, and Google Scholar, for published articles on the skeletal effects of cancer and cancer therapies.
One-hundred-forty-two publications, including journal articles, books, and book chapters, met the inclusion criteria. They included case reports, literature reviews, systematic analyses, and cohort reports. Skeletal effects resulting from cancer and cancer therapies, including hypogonadism, androgen deprivation therapy, estrogen suppression, glucocorticoids/corticosteroids, methotrexate, megestrol acetate, platinum compounds, cyclophosphamide, doxorubicin, interferon-alpha, valproic acid, cyclosporine, vitamin A, NSAIDS, estramustine, ifosfamide, radiotherapy, and combined chemotherapeutic regimens, were identified and described. Skeletal effects of hyperparathyroidism, vitamin D deficiency, gastrectomy, hypophosphatemia, and hyperprolactinemia resulting from cancer therapies were also described.
The publications researched during this review both highlight and emphasize the association between cancer therapies, including chemotherapy and radiotherapy, and skeletal dysfunction.
These studies confirm that cancer survivors experience a more rapid acceleration of bone loss than their age-matched peers who were never diagnosed with cancer. Further studies are needed to better address the skeletal needs of cancer survivors.

Download full-text


Available from: Charles J Stava,
  • Source
    • "Studies on animal models demonstrate that high doses of MTX may damage bone progenitor cells and inhibit proliferation of osteoblasts and intensify bone resorption (Fan et al. 2011). Use of MTX in patients with malignancies was associated with bone mass decrease and osteoporosis (Stava et al. 2009). However, there still remain doubts about the adverse effect of MTX on bone tissue metabolism in RA. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Proinflammatory cytokines and growth factors, which regulate mutual interactions between immune system cells and bone tissue cells, play a major role in the formation of bone changes in rheumatoid arthritis (RA). The aim of the work was to assess serum concentration of osteoprotegerin (OPG), RANKL, Dkk-1 and sclerostin in RA patients compared to a control group and to analyze changes of these concentrations during methotrexate (MTX) therapy. Patients enrolled in the study were 30 women of Caucasian origin aged 30-74 years with RA. Patients with active form of the disease were administered recommended doses of MTX for at least 6 months. The study group was divided into subgroup I-patients with improvement; and subgroup II-patients with no improvement. The control group consisted of 12 healthy women in the age of 41-73. Before MTX therapy, RA patients had higher levels of RANKL (644.97 ± 477.13 vs. 255.19 ± 130.26 pmol/l), lower values of OPG/RANKL (0.01 ± 0.0101 vs. 0.02 ± 0.0078) and higher levels of Dkk-1 protein (1821.32 ± 1060.28 vs. 548.52 ± 36.35 pg/ml) compared to the control group. In the analyzed group of patients (all patients receiving MTX regardless of responder non responder status) after 6 months of therapy, a statistically significant increase in the ratio of OPG/RANKL was found (0.0118 ± 0.0102 vs. 0.0141 ± 0.0118; p = 0.02). The index value of OPG/RANKL differed significantly depending on the resultant effect of treatment (0.01702 ± 0.01274 in the subgroup of improvement vs. 0.00675 ± 0.00289 in the subgroup without improvement). The difference in the mean concentrations of Dkk-1 before and after treatment with MTX between subgroups I and II was statistically significant (p = 0.002). In subgroup I, mean concentration of Dkk-1 decreased after 6 months of treatment with MTX (2054.72 ± 1004.74 vs. 1831.70 ± 851.70 pg/ml); while in subgroup II, the mean concentration of Dkk-1 increased (1214.48 ± 738.32 vs. 2275.01 ± 1385.23 pg/ml). There were no statistically significant changes in the mean concentrations of sclerostin before and after treatment with MTX (in whole group treatment with MTX, in subgroup I, and in subgroup II). The results confirm the presence of disorders of bone metabolism in patients with RA. Treatment with MTX affects the value of the ratio of OPG/RANKL and concentration of Dkk-1.
    Archivum Immunologiae et Therapiae Experimentalis 04/2015; 63(5). DOI:10.1007/s00005-015-0338-x · 3.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors examine communication among groups of cooperating processes in bus-based computer networks. Implementing multicast communication by requiring processes to send a separate copy of each message to every other group member can result in high bandwidth consumption and network traffic congestion. Multicast trees provide an alternative mechanism for process group communication. Unfortunately, constructing an optimal multicast tree for a group of nodes in a general bus-based network is an NP-hard problem. A heuristic algorithm for this purpose is presented. By taking into account the broadcast property of the media, this algorithm performs better than a well-known multicast tree algorithm for point-to-point networks in terms of the average number of bus visits per multicast and the amount of state information required to forward packets
    Communications of the ACM 01/1990; 33(1):29-42. DOI:10.1109/PCCC.1989.37381 · 3.62 Impact Factor
  • Na Yi · Yi Huang ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A novel algorithm for joint CCI cancellation and channel estimation is proposed for BPOFDM. A closed-form algorithm based on least square (LS) is proposed. With this algorithm, the CCI can be cancelled and there is no need to send the training sequence frequently, which increases the spectrum efficiency and lowers the complexity of the system. Also the proposed algorithm is not sensitive to signal to interference ratio (SIR). A properly designed block precoder is proposed for the algorithm. Finally, simulation results demonstrate that the proposed algorithm can effectively mitigate CCI while employing the properly designed precoder thereby, significant improving the system's interference suppression ability without significant bit error rate (BER) performance degradation.
    Communications, 2004 and the 5th International Symposium on Multi-Dimensional Mobile Communications Proceedings. The 2004 Joint Conference of the 10th Asia-Pacific Conference on; 01/2004
Show more